Background Germline mutations driving lung cancer have been infrequently reported in
literature, with EGFR T790M being a known germline mutation identified in 1% of NSCLC …

Background Germline mutations driving lung cancer have been infrequently reported in
literature, with EGFR T790M being a known germline mutation identified in 1% of NSCLC. In …

Background Most patients with EGFR-driven NSCLC harbor exon 19 deletions or exon 20
L858R point mutations, which have established sensitivity to tyrosine kinase inhibitors (TKI) …

Opinion statement EGFR tyrosine kinase inhibitors (TKI) should always be considered when
treating advanced/metastatic non-small cell lung cancer (NSCLC) with atypical EGFR …

© Translational Lung Cancer Research. All rights reserved. Transl Lung Cancer Res 2022;
11 (11): 2167-2169| https://dx. doi. org/10.21037/tlcr-22-683 (exon 19 deletions or exon 21 …

Methods This study retrospectively investigated the molecular profiling of tumor tissue and
treatment outcomes of EGFR-TKI in treatment-naïve patients with EGFR mutant lung …

Background Epidemiological surveys have suggested that lung cancer has inherited
susceptibility and shows familial aggregation. However, the distribution and prevalence of …

Background The identification of epidermal growth factor receptor (EGFR) mutations
represents a milestone in the treatment of advanced non‐small cell lung cancer. Patients …

Background EGFR mutant non-small cell lung cancer (NSCLC) is a heterogeneous disease.
The treatment for frequent EGFR mutations relies on tyrosine kinase inhibitors (TKIs); the …

Non-small cell lung cancers (NSCLC) account for 85% of total lung cancers. Mutation in
EGFR drives the progress of NSCLSs with high mortality rate. Besides the common …